ReviewNeurology. Clinical practice2025
Neuroimaging Findings of CAR T-Cell-Associated Neurotoxicity: A Review.
Review in Neurology. Clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Severe cytotoxic edema after CAR-T cell therapy for acute lymphoblastic leukemia.Arquivos de neuro-psiquiatria · 2026Article
- Cognitive dysfunction associated with cellular immunotherapy for cancer.Neuro-oncology advances · 2026Review
- Molecular and Mechanistic Divergence of Seizures in Pediatric Acute Lymphoblastic Leukemia: CNS Infiltration Versus Chemotherapy-Induced Neurotoxicity.International journal of molecular sciences · 2026Review
- Prospective observational study of magnetic resonance imaging in anti-CD19 CAR T-cell-associated neurotoxicity.Journal of neurology · 2026Observational
- [Imaging of neurological adverse events associated with immunotherapies : Immune checkpoint inhibitors and CAR-T cells].Radiologie (Heidelberg, Germany) · 2026Review
- The neurotoxic legacy of CAR-T cells: where do we stand?Therapeutic advances in neurological disorders · 2026Review
- Real-world clinical outcomes of CAR-T therapy from the Montefiore health system in the Bronx.Annals of hematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor T-cell (CAR-T) therapy has remarkable efficacy in treating refractory hematologic malignancies. However, CAR-T therapy may induce neurotoxic effects in some patients. Common symptoms of neurotoxicity range from early signs such as headache, confusion, delirium, and aphasia to severe manifestations such as seizures, motor weakness, increased intracranial pressure, cerebral edema, and coma. Magnetic resonance imaging (MRI) can offer invaluable insight into resulting abnormalities in the structure, physiology, and function of the central nervous system. This review aims to examine the current literature on brain MRI findings of CAR-T-induced neurotoxicity, elucidating its diagnostic capabilities, clinical implications, and emerging trends in advancing imaging modalities. An improved understanding of neural correlates of CAR-T neurotoxicity is important for early detection, development of neuroprotective strategies, and optimization of CAR-T regimens to maximize therapeutic efficacy while minimizing adverse neurotoxic effects.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.